HIPS — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson HIPS — Sales to customers (Note 9) decreased by 3.7% to $811.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.4%, from $762.00M to $811.00M. Over 2 years (FY 2021 to FY 2024), HIPS — Sales to customers (Note 9) shows an upward trend with a 13.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful product adoption within the HIPS segment, while a decrease may signal competitive pressure or product lifecycle maturity.
Detailed definition
This metric represents the total revenue generated from the Health Technology and Innovative Pharmaceutical Solutions (H...
Peer comparison
Comparable to segment-specific revenue reporting in other diversified healthcare or pharmaceutical conglomerates.
jnj_segment_hips_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $713.00M | $785.00M | $712.00M | $801.00M | $778.00M | $776.00M | $704.00M | $780.00M | $750.00M | $844.00M | $834.00M | $762.00M | $836.00M | $818.00M | $842.00M | $811.00M |
| QoQ Change | — | +10.1% | -9.3% | +12.5% | -2.9% | -0.3% | -9.3% | +10.8% | -3.8% | +12.5% | -1.2% | -8.6% | +9.7% | -2.2% | +2.9% | -3.7% |
| YoY Change | — | — | — | — | +9.1% | -1.1% | -1.1% | +0.3% | -3.4% | — | +6.9% | +1.6% | — | -3.1% | +1.0% | +6.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's hips — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported hips — sales to customers (note 9) of $811.00M in Q3 2025.
- How has Johnson & Johnson's hips — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's hips — sales to customers (note 9) increased by 6.4% year-over-year, from $762.00M to $811.00M.
- What is the long-term trend for Johnson & Johnson's hips — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's hips — sales to customers (note 9) has grown at a 13.1% compound annual growth rate (CAGR), from $2.56B to $3.28B.
- What does hips — sales to customers (note 9) mean?
- The total revenue generated by the company's Health Technology and Innovative Pharmaceutical Solutions segment.